Drugs / Camlipixant
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07684586 | Jul 2026 → Aug 2027 | — | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT06497517 | Jul → Aug 2024 | — | Bellus Health Inc. - a GSK company | Completed | No outcome recorded |
| Phase 1 | NCT06222892 | Feb → Dec 2024 | — | Bellus Health Inc. - a GSK company | Completed | No outcome recorded |
| Phase 1 | NCT05959447 | Jul → Oct 2023 | — | Bellus Health Inc. - a GSK company | Completed | No outcome recorded |
| Phase 1 | NCT05899829 | Jun → Aug 2023 | — | Bellus Health Inc. - a GSK company | Completed | No outcome recorded |
| Phase 1 | NCT05570539 | Oct 2022 → May 2024 | — | Bellus Health Inc. - a GSK company | Completed | No outcome recorded |
| Phase 1 | NCT06179537 | Aug → Oct 2021 | — | Bellus Health Inc. - a GSK company | Completed | No outcome recorded |
| Phase 1 | NCT05244759 | Aug → Sep 2020 | — | Bellus Health Inc. - a GSK company | Completed | No outcome recorded |
| Phase 1 | NCT03638180 | Jul → Oct 2018 | — | Bellus Health Inc. - a GSK company | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT07519395 | Apr 2026 → Mar 2027 expected | irritable bowel syndrome | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT04693195 | Dec 2020 → Oct 2021 | atopic eczema | Bellus Health Inc. - a GSK company | Completed | No outcome recorded |
| Phase 2 | NCT04678206 | Dec 2020 → Oct 2021 | respiratory system disorder | Bellus Health Inc. - a GSK company | Completed | Met primary |
| Phase 2 | NCT03979638 | Jul 2019 → Apr 2020 | — | Bellus Health Inc. - a GSK company | Terminated | Missed primary Stop: Enrollment |
| Phase 33 trials | ||||||
| Phase 3 | NCT07650084 | Nov 2025 → Aug 2027 expected | respiratory system disorder | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT05600777 | Dec 2022 → Jun 2026 overdue | respiratory system disorder | Bellus Health Inc. - a GSK company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05599191 | Oct 2022 → Dec 2025 | respiratory system disorder | Bellus Health Inc. - a GSK company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-17 | GlaxoSmithKline | Results GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC) gsk.com ↗
CALM-1 met its primary endpoint with camlipixant 50mg twice daily showing statistically significant reductions in 24-hour cough frequency versus placebo at week 12. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-17 | GlaxoSmithKline | GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC) gsk.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | camlipixant | “SOOTHE (NCT04678206), a phase 2b, randomized, placebo-controlled trial, evaluated the efficacy and safety of P2X3 antagonist camlipixant in adults with refractory chronic cough” PMID 40043302 ↗ Jun 2025 |
| Known as | AZ-13410937 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095035 ↗ |
| Known as | BLU-5937 | “single dose of camlipixant (BLU-5937) 50 mg tablet” NCT05899829 ↗ |
| Known as | GSK5464714 | “Camlipixant (GSK5464714)” NCT06497517 ↗ |
| Known as | NEO-5937 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095035 ↗ |
| Action | Inhibit | “selective P2X3 receptor antagonist” NCT03638180 ↗1“P2X purinoceptor 3 antagonist” CHEMBL5095035 ↗ |
| Modality | Small molecule | — CHEMBL5095035 ↗ |
| Route | Oral | “BLU-5937 administered orally” NCT03638180 ↗ |
| Target | P2RX3 | “P2X purinoceptor 3 antagonist” CHEMBL5095035 ↗ |